Literature DB >> 348139

Xanthine nephropathy during chemotherapy in deficiency of hypoxanthine-guanine phosphoribosyltransferase.

G A Gomez, L Stutzman, T M Chu.   

Abstract

We describe an episode of obstructive uropathy produced by xanthine precipitation in the tubules of the kidney of a patient with histiocytic lymphoma during intensive chemotherapy, despite allopurinol therapy. Urinary oxypurine-uric acid ratio suggested a subclinical deficiency of hypoxanthine-guanine phosphoribosyltransferase. Results of an assay of this enzyme confirmed the abnormality. Both parents and three brothers of the patient had normal enzyme activity. The continued importance of adequate hydration for patients who receive allopurinol during initial periods of cancer therapy is emphasized.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 348139     DOI: 10.1001/archinte.138.6.1017

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  7 in total

Review 1.  Chemotherapy-associated renal dysfunction.

Authors:  Vaibhav Sahni; Devasmita Choudhury; Ziauddin Ahmed
Journal:  Nat Rev Nephrol       Date:  2009-06-30       Impact factor: 28.314

2.  Use and abuse of allopurinol.

Authors:  J S Cameron; H A Simmonds
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-13

3.  Acute renal failure due to bilateral xanthine urolithiasis in a boy with Lesch-Nyhan syndrome.

Authors:  Przemysław Sikora; Monika Pijanowska; Marek Majewski; Beata Bieniaś; Halina Borzecka; Małgorzata Zajczkowska
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

4.  Acute renal failure from xanthine nephropathy during management of acute leukemia.

Authors:  Christopher LaRosa; Laura McMullen; Suzanne Bakdash; Demetrius Ellis; Lakshmanan Krishnamurti; Hsi-Yang Wu; Michael L Moritz
Journal:  Pediatr Nephrol       Date:  2006-10-13       Impact factor: 3.714

Review 5.  Gout, uric acid and purine metabolism in paediatric nephrology.

Authors:  J S Cameron; F Moro; H A Simmonds
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

6.  Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects.

Authors:  Seonghae Yoon; Donghoon Shin; Howard Lee; In-Jin Jang; Kyung-Sang Yu
Journal:  Drug Des Devel Ther       Date:  2015-08-31       Impact factor: 4.162

7.  The renal phenotype of allopurinol-treated HPRT-deficient mouse.

Authors:  Cristina Zennaro; Federica Tonon; Paola Zarattini; Milan Clai; Alessandro Corbelli; Michele Carraro; Marialaura Marchetti; Luca Ronda; Gianluca Paredi; Maria Pia Rastaldi; Riccardo Percudani
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.